<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Clonidine</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00575</strong>&#160; (APRD00174, DB07566)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>Clonidine, an imidazoline-derivative hypotensive agent is a centrally-acting &#945;<sub>2</sub>-adrenergic agonist. It crosses the blood-brain barrier and acts in the hypothalamus to induce a decrease in blood pressure. It may also be administered as an epidural infusion as an adjunct treatment in the management of severe cancer pain that is not relieved by opiate analgesics alone. Clonidine may be used for differential diagnosis of pheochromocytoma in hypertensive patients. Other uses for clonidine include prophylaxis of vascular migraine headaches, treatment of severe dysmenorrhea, management of vasomotor symptoms associated with menopause, rapid detoxification in the management of opiate withdrawal, treatment of alcohol withdrawal used in conjunction with benzodiazepines, management of nicotine dependence, topical use to reduce intraocular pressure in the treatment of open-angle and secondary glaucoma and hemorrhagic glaucoma associated with hypertension, and in the treatment of attention-deficit hyperactivity disorder (<span class="caps">ADHD</span>). Clonidine also exhibits some peripheral activity.</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00575/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00575/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00575.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00575.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00575.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00575.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00575.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00575">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Chlofazoline</td><td><span class="wishart wishart-not-available">Not Available</span></td><td>IS</td></tr><tr><td>Clonidin</td><td>German</td><td>INN</td></tr><tr><td>Clonidina</td><td>Spanish</td><td>INN</td></tr><tr><td>Clonidinum</td><td>Latin</td><td>INN</td></tr></tbody></table></td></tr><tr><th>Salts</th><td class="table-container"><table class="inner">
  <thead>
    <tr>
      <th>Name/CAS</th>
      <th>Structure</th>
      <th>Properties</th>
      <th></th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>
          <strong>Clonidine Hydrochloride</strong>
          <div class="cas">4205-91-8</div>
        </td>
        <td><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DBSALT000538/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DBSALT000538/thumb.png"></a></td>
        <td>
            <ul>
              <li>InChI Key: ZNIFSRGNXRYGHF-UHFFFAOYSA-N</li>
              <li>Monoisotopic Mass: 264.994030456</li>
              <li>Average Mass: 266.555</li>
            </ul>
        </td>
        <td><a class="btn btn-default btn-xs" href="/salts/DBSALT000538">DBSALT000538</a></td>
      </tr>
  </tbody>
</table></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Catapres</td><td>Boehringer Ingelheim</td></tr><tr><td>Catapres-TTS</td><td>Boehringer Ingelheim</td></tr><tr><td>Catapresan</td><td>Boehringer Ingelheim</td></tr><tr><td>Catapressan</td><td>Boehringer Ingelheim</td></tr><tr><td>Dixarit</td><td>Boehringer Ingelheim</td></tr><tr><td>Duraclon</td><td>Bioniche</td></tr><tr><td>Isoglaucon</td><td>Agepha</td></tr><tr><td>Kapvay</td><td>Shionogi</td></tr><tr><td>Nexiclon</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Run Rui</td><td>Bausch &amp; Lomb</td></tr><tr><td>Velaril</td><td>Roemmers</td></tr><tr><td>Winpress</td><td>Winston</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="mixtures"><thead><tr><th>Brand Name</th><th>Ingredients</th></tr></thead><tbody><tr><td>Arkamin-H</td><td>Clonidine and Hydrochlorothiazide</td></tr><tr><td>Clorpres</td><td>Clonidine and Chlortalidone</td></tr><tr><td>Combipres 0.1/15 Tab</td><td>Chlorthalidone + Clonidine Hydrochloride</td></tr></tbody></table></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/antihypertensive-agents">Antihypertensive Agents</a></li>
<li><a href="/mesh/sympatholytics">Sympatholytics</a></li>
<li><a href="/mesh/analgesics">Analgesics</a></li>
<li><a href="/mesh/adrenergic-alpha-2-receptor-agonists">Adrenergic alpha-2 Receptor Agonists</a></li></ul></td></tr><tr><th>CAS number</th><td>4205-90-7</td></tr><tr><th>Weight</th><td>Average: 230.094<br>Monoisotopic: 229.017352717</td></tr><tr><th>Chemical Formula</th><td>C<sub>9</sub>H<sub>9</sub>Cl<sub>2</sub>N<sub>3</sub></td></tr><tr><th>InChI Key</th><td>GJSURZIOUXUGAL-UHFFFAOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C9H9Cl2N3/c10-6-2-1-3-7(11)8(6)14-9-12-4-5-13-9/h1-3H,4-5H2,(H2,12,13,14)</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">N-(2,6-dichlorophenyl)-4,5-dihydro-1H-imidazol-2-amine</div></td></tr><tr><th>SMILES</th><td><div class="wrap">ClC1=CC=CC(Cl)=C1NC1=NCCN1</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Benzenoids</td></tr><tr><th>Class</th><td>Benzene and Substituted Derivatives</td></tr><tr><th>Subclass</th><td>Halobenzenes</td></tr><tr><th>Direct parent</th><td>Dichlorobenzenes</td></tr><tr><th>Alternative parents</th><td>Aryl Chlorides; Guanidines; Polyamines; Organochlorides</td></tr><tr><th>Substituents</th><td>aryl chloride; aryl halide; guanidine; polyamine; organochloride; organohalogen; amine; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the dichlorobenzenes. These are compounds containing a benzene with exactly two chlorine atoms attached to it.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>May be used as an adjunct in the treatment of hypertension, as an epidural infusion as an adjunct treatment in the management of severe cancer pain that is not relieved by opiate analgesics alone, for differential diagnosis of pheochromocytoma in hypertensive patients, prophylaxis of vascular migraine headaches, treatment of severe dysmenorrhea, management of vasomotor symptoms associated with menopause, rapid detoxification in the management of opiate withdrawal, treatment of alcohol withdrawal used in conjunction with benzodiazepines, management of nicotine dependence, topical use to reduce intraocular pressure in the treatment of open-angle and secondary glaucoma and hemorrhagic glaucoma associated with hypertension, and in the treatment of attention-deficit hyperactivity disorder (ADHD).</td></tr><tr><th>Pharmacodynamics</th><td>Clonidine is an &#945;-adrenergic agent that acts specifically on &#945;<sub>2</sub>-receptors. &#945;<sub>2</sub>-receptors regulate a number of signaling pathways mediated by multiple G<sub>i</sub> proteins, G&#945;<sub>i1</sub>, G&#945;<sub>i2</sub>, and G&amp;alpha<sub>i3</sub>. Stimulation of &#945;<sub>2</sub>-receptors mediates effects such as inhibition of adenylyl cyclase, stimulation fo phospholipase D, stimulation of mitogen-activated protein kinases, stimulation of K<sup>+</sup> currents and inhibition of Ca<sup>2+</sup> currents. Three G-protein coupled &#945;<sub>2</sub>-receptor subtypes have been identified: &#945;<sub>2A</sub>, &#945;<sub>2B</sub>, and &#945;<sub>2C</sub>. Each subtype has a unique pattern of tissue distribution in the central nervous system and peripheral tissues. The &#945;<sub>2A</sub>-receptor is widely distributed throughout the central nervous system; it is found in the locus coeruleus, brain stem nuclei, cerebral cortex, septum, hypothalamus, and hippocampus. &#945;<sub>2A</sub>-receptors are also expressed in the kidneys, spleen, thymus, lung and salivary glands. The &#945;<sub>2C</sub>-receptor is primarily expressed in the central nervous system, including the striatum, olfactory tubercle, hippocampus and cerebral cortex. Low levels of the &#945;<sub>2C</sub>-subtype are also found in the kidneys. The &#945;<sub>2B</sub>-receptor is located primarily in the periphery (kidney, liver, lung and heart) with low levels of expression in the thalamic nuclei of the central nervous system. The &#945;<sub>2A</sub>- and &#945;<sub>2C</sub>-receptors are located presynaptically and inhibit the released of noradrenaline from sympathetic nerves. Stimulation of these receptors decreases sympathetic tone, resulting in decreases in blood pressure and heart rate. Sedation and analgesia is mediated by centrally located &#945;<sub>2A</sub>-receptors, while peripheral &#945;<sub>2B</sub>-receptors mediate constriction of vascular smooth muscle. &#945;<sub>2A</sub>-Receptors also mediate essential components of the analgesic effect of nitrous oxide in the spinal cord. Clonidine stimulates all three &#945;<sub>2</sub>-receptor subtypes with similar potency. Its actions in the nervous system decreases blood pressure in patients with hypertension and decreases sympathetic overactivity in patients undergoing opioid withdrawal. Clonidine is also a potent sedative and analgesic and can prevent post-operative shivering in intensive and post-operative care. Its use in differential diagnosis of pheochromocytoma owes to the fact that hypertension in patients with pheochromocytoma is refractory to antihypertensive treatment with clonidine. </td></tr><tr><th>Mechanism of action</th><td>See Pharmacology section above. </td></tr><tr><th>Absorption</th><td>Well absorbed following oral administration. Bioavailability following chronic administration is approximately 65%.</td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td>20-40%, primarily to albumin</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Hepatic. Metabolized via minor pathways. The major metabolite, <i>p</i>-hydroxyclonidine, is present in concentrations less than 10% of those of unchanged clonidine in urine. Four metabolites have been detected, but only <i>p</i>-hydroxyclonidine has been identified. </p><table class="table-standard table-condensed" id="experimental-properties"><thead><tr><th>Substrate</th><th>Enzymes</th><th colspan="2">Product</th></tr></thead><tbody><tr><td>Clonidine</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002363" target="_blank">Cytochrome P450 2D6</a></li>
<li><a href="/biodb/bio_entities/BE0002433" target="_blank">Cytochrome P450 1A2</a></li>
<li><a href="/biodb/bio_entities/BE0002638" target="_blank">Cytochrome P450 3A4</a></li>
<li><a href="/biodb/bio_entities/BE0003543" target="_blank">Cytochrome P450 1A1</a></li>
<li><a href="/biodb/bio_entities/BE0002362" target="_blank">Cytochrome P450 3A5</a></li></ul></td><td><a href="/metabolites/DBMET00468">4-Hydroxyclonidine</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/477">Details</a></td></tr></tbody></table></td></tr><tr><th>Route of elimination</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Half life</th><td>6-20 hours; 40-60% is excreted in urine unchanged, 20% is excreted in feces. Less than 10% is excreted by <i>p</i>-hydroxyclonidine. </td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td>Oral LD<sub>50</sub> is 150 mg/kg in rat and 30 mg/kg in dog. Symptoms of overdose include constriction of pupils of the eye, drowsiness, high blood pressure followed by a drop in pressure, irritability, low body temperature, slowed breathing, slowed heartbeat, slowed reflexes, and weakness.</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9632</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.9402</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.8866</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.6305</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9061</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8383</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Inhibitor
        </td>
        <td>0.745</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.8219</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.6984</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-substrate</td>
        <td>0.6353</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8998</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.7681</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Inhibitor</td>
        <td>0.8931</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8732</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8332</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.803</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.9133
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.9303
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.9949
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          3.5030 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.7232
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.8905
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Boehringer ingelheim</li>
<li>Aveva drug delivery systems inc</li>
<li>Mylan technologies inc</li>
<li>Tris pharma inc</li>
<li>Pharmaforce inc</li>
<li>Bioniche pharma usa llc</li>
<li>Actavis elizabeth llc</li>
<li>American therapeutics inc</li>
<li>Dava pharmaceuticals inc</li>
<li>Duramed pharmaceuticals inc sub barr laboratories inc</li>
<li>Impax laboratories inc</li>
<li>Interpharm inc</li>
<li>Mutual pharmaceutical co inc</li>
<li>Mylan pharmaceuticals inc</li>
<li>Par pharmaceutical inc</li>
<li>Sandoz inc</li>
<li>Teva pharmaceuticals usa inc</li>
<li>Unichem laboratories ltd</li>
<li>Vintage pharmaceuticals llc</li>
<li>Warner chilcott div warner lambert co</li>
<li>Watson laboratories inc</li>
<li>Shionogi pharma inc</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.aaipharma.com">AAIPharma Inc.</a></li>
<li><a href="http://www.actavis.com">Actavis Group</a></li>
<li>Advanced Pharmaceutical Services Inc.</li>
<li>Alza Corp.</li>
<li><a href="http://www.americanregent.com">American Regent</a></li>
<li><a href="http://www.amerisourcebergen.com">Amerisource Health Services Corp.</a></li>
<li>Apotheca Inc.</li>
<li><a href="http://www.apppharma.com">APP Pharmaceuticals</a></li>
<li><a href="http://orders.a-smeds.com">A-S Medication Solutions LLC</a></li>
<li><a href="http://www.bionichepharmausa.com">Bioniche Pharma</a></li>
<li><a href="http://www.bpipack.com">Blenheim Pharmacal</a></li>
<li><a href="http://www.boehringer-ingelheim.com">Boehringer Ingelheim Ltd.</a></li>
<li><a href="http://bryantranchprepack.com">Bryant Ranch Prepack</a></li>
<li><a href="http://www.cardinal.com">Cardinal Health</a></li>
<li><a href="http://www.chcsct.com">Central Texas Community Health Centers</a></li>
<li>Comprehensive Consultant Services Inc.</li>
<li>Coupler Enterprises Inc.</li>
<li><a href="http://www.davapharma.com">DAVA Pharmaceuticals</a></li>
<li>Dept Health Central Pharmacy</li>
<li>Direct Dispensing Inc.</li>
<li><a href="http://www.drxdispensing.com">Dispensing Solutions</a></li>
<li><a href="http://www.dhscorp.com">Diversified Healthcare Services Inc.</a></li>
<li><a href="http://www.globalphar.com">Global Pharmaceuticals</a></li>
<li>Heartland Repack Services LLC</li>
<li><a href="http://www.innoviantpharmacy.com">Innoviant Pharmacy Inc.</a></li>
<li>Lake Erie Medical and Surgical Supply</li>
<li>Liberty Pharmaceuticals</li>
<li><a href="http://www.majorpharmaceuticals.com">Major Pharmaceuticals</a></li>
<li><a href="http://www.mckesson.com">Mckesson Corp.</a></li>
<li><a href="http://www.medisca.com">Medisca Inc.</a></li>
<li><a href="http://www.unitdosesupply.com">Murfreesboro Pharmaceutical Nursing Supply</a></li>
<li>Mutual Pharmaceutical Co.</li>
<li><a href="http://www.mylan.com">Mylan</a></li>
<li>Neighborcare Repackaging Inc.</li>
<li>Neuman Distributors Inc.</li>
<li><a href="http://www.nucarerx.com">Nucare Pharmaceuticals Inc.</a></li>
<li><a href="http://www.palmettopharm.com">Palmetto Pharmaceuticals Inc.</a></li>
<li><a href="http://www.parpharm.com">Par Pharmaceuticals</a></li>
<li>PCA LLC</li>
<li><a href="http://www.pdrx.com">PD-Rx Pharmaceuticals Inc.</a></li>
<li>Pharmaceutical Utilization Management Program VA Inc.</li>
<li><a href="http://www.pharmaforceinc.com">Pharmaforce Inc.</a></li>
<li><a href="http://www.pharmedixrx.com">Pharmedix</a></li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li>
<li><a href="http://www.preferredpharmaceuticals.com">Preferred Pharmaceuticals Inc.</a></li>
<li>Prepackage Specialists</li>
<li><a href="http://www.prepaksys.com">Prepak Systems Inc.</a></li>
<li><a href="http://www.worldoftest.com">Qualitest</a></li>
<li><a href="http://www.rebelrx.com">Rebel Distributors Corp.</a></li>
<li>Redpharm Drug</li>
<li><a href="http://www.remedyrepack.com">Remedy Repack</a></li>
<li><a href="http://www.richmondpharmacy.ca">Richmond Pharmacy</a></li>
<li><a href="http://www.sandhillspackaging.com">Sandhills Packaging Inc.</a></li>
<li><a href="http://www.southwoodhealthcare.com">Southwood Pharmaceuticals</a></li>
<li><a href="http://statrxusa.exporterus.com">Stat Rx Usa</a></li>
<li>Tya Pharmaceuticals</li>
<li><a href="http://www.udllabs.com">UDL Laboratories</a></li>
<li><a href="http://www.unichemlabs.com">Unichem Laboratories Ltd.</a></li>
<li><a href="http://www.urlpharma.com">United Research Laboratories Inc.</a></li>
<li>Vangard Labs Inc.</li>
<li>Vintage Pharmaceuticals Inc.</li>
<li><a href="http://www.west-ward.com">West-Ward Pharmaceuticals</a></li>
<li><a href="http://www.xanodyne.com">Xanodyne Pharmaceuticals Inc.</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Injection, solution</td><td>Epidural</td><td>100 mcg/ml</td></tr><tr><td>Injection, solution, concentrate</td><td>Epidural</td><td>500 mcg/ml</td></tr><tr><td>Patch</td><td>Transdermal</td><td>0.1 mg/24 hours</td></tr><tr><td>Patch</td><td>Transdermal</td><td>0.2 mg/24 hours</td></tr><tr><td>Patch</td><td>Transdermal</td><td>0.3 mg/24 hours</td></tr><tr><td>Tablet</td><td>Oral</td><td>0.025 mg</td></tr><tr><td>Tablet</td><td>Oral</td><td>0.1 mg</td></tr><tr><td>Tablet</td><td>Oral</td><td>0.2 mg</td></tr><tr><td>Tablet</td><td>Oral</td><td>0.3 mg</td></tr></tbody></table></td></tr><tr><th>Prices</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="prices"><thead><tr><th>Unit description</th><th>Cost</th><th>Unit</th></tr></thead><tbody><tr><td>Catapres-TTS-3 4 0.3 mg/24hr Patches Box</td><td>328.42USD</td><td>box</td></tr><tr><td>CloNIDine HCl 4 0.3 mg/24hr Patches Box</td><td>279.9USD</td><td>box</td></tr><tr><td>Catapres-TTS-2 4 0.2 mg/24hr Patches Box</td><td>236.75USD</td><td>box</td></tr><tr><td>CloNIDine HCl 4 0.2 mg/24hr Patches Box</td><td>201.75USD</td><td>box</td></tr><tr><td>Catapres-TTS-1 4 0.1 mg/24hr Patches Box</td><td>141.08USD</td><td>box</td></tr><tr><td>CloNIDine HCl 4 0.1 mg/24hr Patches Box</td><td>119.84USD</td><td>box</td></tr><tr><td>Catapres-tts 3 patch</td><td>78.95USD</td><td>patch</td></tr><tr><td>Clonidine 0.3 mg/day patch</td><td>67.28USD</td><td>patch</td></tr><tr><td>Clonidine hcl powder</td><td>53.09USD</td><td>g</td></tr><tr><td>Clonidine 0.2 mg/day patch</td><td>48.5USD</td><td>patch</td></tr><tr><td>Duraclon 500 mcg/ml vial</td><td>47.4USD</td><td>ml</td></tr><tr><td>Catapres-tts 2 patch</td><td>39.23USD</td><td>patch</td></tr><tr><td>Clonidine 0.1 mg/day patch</td><td>28.81USD</td><td>patch</td></tr><tr><td>Catapres-tts 1 patch</td><td>21.18USD</td><td>patch</td></tr><tr><td>Clonidine 5000 mcg/10 ml vial</td><td>21.0USD</td><td>ml</td></tr><tr><td>Duraclon 0.1 mg/ml vial</td><td>14.4USD</td><td>ml</td></tr><tr><td>Clonidine 1000 mcg/10 ml vial</td><td>5.04USD</td><td>ml</td></tr><tr><td>Catapres 0.3 mg tablet</td><td>2.98USD</td><td>tablet</td></tr><tr><td>Catapres 0.2 mg tablet</td><td>2.35USD</td><td>tablet</td></tr><tr><td>Catapres 0.1 mg tablet</td><td>1.57USD</td><td>tablet</td></tr><tr><td>Clonidine hcl 0.3 mg tablet</td><td>0.5USD</td><td>tablet</td></tr><tr><td>Clonidine hcl 0.2 mg tablet</td><td>0.35USD</td><td>tablet</td></tr><tr><td>Catapres 0.2 mg Tablet</td><td>0.35USD</td><td>tablet</td></tr><tr><td>Apo-Clonidine 0.2 mg Tablet</td><td>0.33USD</td><td>tablet</td></tr><tr><td>Novo-Clonidine 0.2 mg Tablet</td><td>0.33USD</td><td>tablet</td></tr><tr><td>Nu-Clonidine 0.2 mg Tablet</td><td>0.33USD</td><td>tablet</td></tr><tr><td>Dixarit 0.025 mg Tablet</td><td>0.28USD</td><td>tablet</td></tr><tr><td>Clonidine hcl 0.1 mg tablet</td><td>0.24USD</td><td>tablet</td></tr><tr><td>Catapres 0.1 mg Tablet</td><td>0.19USD</td><td>tablet</td></tr><tr><td>Apo-Clonidine 0.1 mg Tablet</td><td>0.18USD</td><td>tablet</td></tr><tr><td>Novo-Clonidine 0.1 mg Tablet</td><td>0.18USD</td><td>tablet</td></tr><tr><td>Nu-Clonidine 0.1 mg Tablet</td><td>0.18USD</td><td>tablet</td></tr><tr><td>Apo-Clonidine 0.025 mg Tablet</td><td>0.16USD</td><td>tablet</td></tr><tr><td>Novo-Clonidine 0.025 mg Tablet</td><td>0.16USD</td><td>tablet</td></tr></tbody></table><div class="alert alert-warning clearfix">DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.</div></td></tr><tr><th>Patents</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="patents"><thead><tr><th>Country</th><th>Patent Number</th><th>Approved</th><th>Expires (estimated)</th></tr></thead><tbody><tr><td>United States</td><td>5869100</td><td>1993-10-13</td><td>2013-10-13</td></tr></tbody></table></td></tr><tr id="properties"><th class="divider" colspan="2">Properties</th></tr><tr><th>State</th><td>solid</td></tr><tr><th>Experimental Properties</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><tr><th class="head-medium">Property</th><th class="head-large">Value</th><th>Source</th></tr><tr><td>melting point</td><td>305</td><td>3,202,660</td></tr><tr><td>water solubility</td><td>Appreciable</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>logP</td><td>1.59</td><td>HANSCH,C &amp; LEO,AJ (1985)</td></tr><tr><td>Caco2 permeability</td><td>-4.59</td><td>ADME Research, USCD</td></tr><tr><td>pKa</td><td>8.05 (at 25 &#176;C)</td><td>KONTTURI,K &amp; MURTOMAKI,L (1992)</td></tr></table></td></tr><tr><th>Predicted Properties</th><td class="data-table-container"><table class="table table-condensed table-striped"><thead><tr><th class="head-medium">Property</th><th class="head-large">Value</th><th>Source</th></tr></thead><tbody><tr><td>water solubility</td><td>4.80e-01 g/l</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>logP</td><td>2.55</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>logP</td><td>2.49</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#logp_logd">ChemAxon</a></td></tr><tr><td>logS</td><td>-2.7</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>pKa (strongest basic)</td><td>8.16</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>physiological charge</td><td>1</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>hydrogen acceptor count</td><td>3</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#h_bond">ChemAxon</a></td></tr><tr><td>hydrogen donor count</td><td>2</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#h_bond">ChemAxon</a></td></tr><tr><td>polar surface area</td><td>36.42</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topolgical_surface">ChemAxon</a></td></tr><tr><td>rotatable bond count</td><td>1</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topology_analysis">ChemAxon</a></td></tr><tr><td>refractivity</td><td>59.09</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#refractivity">ChemAxon</a></td></tr><tr><td>polarizability</td><td>21.7</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>number of rings</td><td>2</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topology_analysis">ChemAxon</a></td></tr><tr><td>bioavailability</td><td>1</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>rule of five</td><td>Yes</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>Ghose filter</td><td>Yes</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>Veber's rule</td><td>Yes</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>MDDR-like rule</td><td>No</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="references"><th class="divider" colspan="2">References</th></tr><tr><th>Synthesis Reference</th><td><span class="citations"><p>David R. Pierce, William D. Dean, Michael E. Deason, &#8220;Process for preparation of clonidine derivatives.&#8221; U.S. Patent US5684156, issued October, 1968.</p></span><a class="wishart-link-out" href="https://www.google.com/?tbm=pts#q=5684156&amp;tbm=pts" target="_blank">US5684156 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><th>General Reference</th><td><span class="citations"><ol>
	<li>Schapiro NA: &#8220;Dude, you don&#8217;t have Tourette&#8217;s:&#8221; Tourette&#8217;s syndrome, beyond the tics. Pediatr Nurs. 2002 May-Jun;28(3):243-6, 249-53. <a href="http://www.ncbi.nlm.nih.gov/pubmed/12087644">Pubmed</a></li>
	<li>Hossmann V, Maling TJ, Hamilton CA, Reid JL, Dollery CT: Sedative and cardiovascular effects of clonidine and nitrazepam. Clin Pharmacol Ther. 1980 Aug;28(2):167-76. <a href="http://www.ncbi.nlm.nih.gov/pubmed/7398184">Pubmed</a></li>
</ol></span></td></tr><tr><th>External Links</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Resource</th><th>Link</th></tr></thead><tbody><tr><td>KEGG Drug</td><td><a class="wishart-link-out" href="http://www.genome.jp/dbget-bin/www_bget?drug:D00281" target="_blank">D00281 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PubChem Compound</td><td><a class="wishart-link-out" href="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=2803" target="_blank">2803 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PubChem Substance</td><td><a class="wishart-link-out" href="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=46508119" target="_blank">46508119 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>ChemSpider</td><td><a class="wishart-link-out" href="http://www.chemspider.com/Chemical-Structure.2701.html" target="_blank">2701 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>ChEBI</td><td><a class="wishart-link-out" href="http://www.ebi.ac.uk/chebi/searchId.do?chebiId=46631" target="_blank">46631 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>ChEMBL</td><td><a class="wishart-link-out" href="http://www.ebi.ac.uk/chembldb/index.php/compound/inspect/CHEMBL134" target="_blank">CHEMBL134 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Therapeutic Targets Database</td><td><a class="wishart-link-out" href="http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP000231" target="_blank">DAP000231 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PharmGKB</td><td><a class="wishart-link-out" href="http://www.pharmgkb.org/drug/PA449051" target="_blank">PA449051 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>IUPHAR</td><td><a class="wishart-link-out" href="http://www.iuphar-db.org/DATABASE/LigandDisplayForward?ligandId=516" target="_blank">516 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Guide to Pharmacology</td><td><a class="wishart-link-out" href="http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=516" target="_blank">516 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>HET</td><td><a class="wishart-link-out" href="http://www.ebi.ac.uk/msd-srv/chempdb/cgi-bin/cgi.pl?FUNCTION=getByCode&amp;CODE=CLU" target="_blank">CLU <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Drug Product Database</td><td><a class="wishart-link-out" href="http://205.193.93.51/dpdonline/searchRequest.do?din=2247608" target="_blank">2247608 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>RxList</td><td><a class="wishart-link-out" href="http://www.rxlist.com/cgi/generic/clonidin.htm" target="_blank">http://www.rxlist.com/cgi/generic/clonidin.htm <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Drugs.com</td><td><a class="wishart-link-out" href="http://www.drugs.com/clonidine.html" target="_blank">http://www.drugs.com/clonidine.html <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PDRhealth</td><td><a class="wishart-link-out" href="http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/cat1072.shtml" target="_blank">http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/cat1072.shtml <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Wikipedia</td><td><a class="wishart-link-out" href="http://en.wikipedia.org/wiki/Clonidine" target="_blank">Clonidine <span class="glyphicon glyphicon-new-window"> </span></a></td></tr></tbody></table></td></tr><tr><th>ATC Codes</th><td>C02AC01<ul class="atc-drug-tree"><li><a href="/atc/C#C">C &#8212; CARDIOVASCULAR SYSTEM</a></li><li><a href="/atc/C02#C02">C02 &#8212; ANTIHYPERTENSIVES</a></li><li><a href="/atc/C02A#C02A">C02A &#8212; ANTIADRENERGIC AGENTS, CENTRALLY ACTING</a></li><li><a href="/atc/C02AC#C02AC">C02AC &#8212; Imidazoline receptor agonists</a></li></ul>N02CX02<ul class="atc-drug-tree"><li><a href="/atc/N#N">N &#8212; NERVOUS SYSTEM</a></li><li><a href="/atc/N02#N02">N02 &#8212; ANALGESICS</a></li><li><a href="/atc/N02C#N02C">N02C &#8212; ANTIMIGRAINE PREPARATIONS</a></li><li><a href="/atc/N02CX#N02CX">N02CX &#8212; Other antimigraine preparations</a></li></ul>S01EA04<ul class="atc-drug-tree"><li><a href="/atc/S#S">S &#8212; SENSORY ORGANS</a></li><li><a href="/atc/S01#S01">S01 &#8212; OPHTHALMOLOGICALS</a></li><li><a href="/atc/S01E#S01E">S01E &#8212; ANTIGLAUCOMA PREPARATIONS AND MIOTICS</a></li><li><a href="/atc/S01EA#S01EA">S01EA &#8212; Sympathomimetics in glaucoma therapy</a></li></ul>S01EA03<ul class="atc-drug-tree"><li><a href="/atc/S#S">S &#8212; SENSORY ORGANS</a></li><li><a href="/atc/S01#S01">S01 &#8212; OPHTHALMOLOGICALS</a></li><li><a href="/atc/S01E#S01E">S01E &#8212; ANTIGLAUCOMA PREPARATIONS AND MIOTICS</a></li><li><a href="/atc/S01EA#S01EA">S01EA &#8212; Sympathomimetics in glaucoma therapy</a></li></ul></td></tr><tr><th>AHFS Codes</th><td><ul><li>24:08.16</li></ul></td></tr><tr><th>PDB Entries</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>FDA label</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>MSDS</th><td><a href="/system/msds/DB00575.pdf?1265922748">show</a>(73.8 KB)</td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB01193">Acebutolol</a></td><td>Increased hypertension when clonidine stopped</td></tr><tr><td><a href="/drugs/DB00321">Amitriptyline</a></td><td>The tricyclic antidepressant, amitriptyline, decreases the effect of clonidine.</td></tr><tr><td><a href="/drugs/DB00543">Amoxapine</a></td><td>The tricyclic antidepressant, amoxapine, decreases the effect of clonidine.</td></tr><tr><td><a href="/drugs/DB00335">Atenolol</a></td><td>Increased hypertension when clonidine stopped</td></tr><tr><td><a href="/drugs/DB00195">Betaxolol</a></td><td>Increased hypertension when clonidine stopped</td></tr><tr><td><a href="/drugs/DB01295">Bevantolol</a></td><td>Increased hypertension when clonidine stopped</td></tr><tr><td><a href="/drugs/DB00612">Bisoprolol</a></td><td>Increased hypertension when clonidine stopped</td></tr><tr><td><a href="/drugs/DB00521">Carteolol</a></td><td>Increased hypertension when clonidine stopped</td></tr><tr><td><a href="/drugs/DB01136">Carvedilol</a></td><td>Increased hypertension when clonidine stopped</td></tr><tr><td><a href="/drugs/DB01242">Clomipramine</a></td><td>The tricyclic antidepressant, clomipramine, may decrease the effect of clonidine.</td></tr><tr><td><a href="/drugs/DB01151">Desipramine</a></td><td>The tricyclic antidepressant, desipramine, decreases the effect of clonidine.</td></tr><tr><td><a href="/drugs/DB01142">Doxepin</a></td><td>The tricyclic antidepressant, doxepin, decreases the effect of clonidine.</td></tr><tr><td><a href="/drugs/DB00187">Esmolol</a></td><td>Increased hypertension when clonidine stopped</td></tr><tr><td><a href="/drugs/DB00458">Imipramine</a></td><td>The tricyclic antidepressant, imipramine, decreases the effect of clonidine.</td></tr><tr><td><a href="/drugs/DB00598">Labetalol</a></td><td>Increased hypertension when clonidine stopped</td></tr><tr><td><a href="/drugs/DB00264">Metoprolol</a></td><td>Increased hypertension when clonidine stopped</td></tr><tr><td><a href="/drugs/DB04896">Milnacipran</a></td><td>Because Savella inhibits norepinephrine reuptake, co-administration with clonidine may inhibit clonidine's anti-hypertensive effect.</td></tr><tr><td><a href="/drugs/DB00370">Mirtazapine</a></td><td>Possible hypertensive crisis</td></tr><tr><td><a href="/drugs/DB01203">Nadolol</a></td><td>Increased hypertension when clonidine stopped</td></tr><tr><td><a href="/drugs/DB00540">Nortriptyline</a></td><td>The tricyclic antidepressant, nortriptyline, decreases the effect of clonidine.</td></tr><tr><td><a href="/drugs/DB01580">Oxprenolol</a></td><td>Increased hypertension when clonidine stopped</td></tr><tr><td><a href="/drugs/DB01359">Penbutolol</a></td><td>Increased hypertension when clonidine stopped</td></tr><tr><td><a href="/drugs/DB00960">Pindolol</a></td><td>Increased hypertension when clonidine stopped</td></tr><tr><td><a href="/drugs/DB01297">Practolol</a></td><td>Increased hypertension when clonidine stopped</td></tr><tr><td><a href="/drugs/DB00571">Propranolol</a></td><td>Increased hypertension when clonidine stopped</td></tr><tr><td><a href="/drugs/DB00344">Protriptyline</a></td><td>The tricyclic antidepressant, protriptyline, decreases the effect of clonidine.</td></tr><tr><td><a href="/drugs/DB00489">Sotalol</a></td><td>Increased hypertension when clonidine stopped</td></tr><tr><td><a href="/drugs/DB00373">Timolol</a></td><td>Increased hypertension when clonidine stopped</td></tr><tr><td><a href="/drugs/DB00374">Treprostinil</a></td><td>Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. </td></tr><tr><td><a href="/drugs/DB00726">Trimipramine</a></td><td>Trimipramine may reduce the antihypertensive effect of the alpha2-agonist, Clonidine. Trimipramine may also increase the rebound hypertensive effect of Clonidine. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Clonidine if Trimipramine is initiated, discontinued or dose changed. Clonidine should be withdrawn very gradually to reduce the risk of hypertensive crisis.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Avoid alcohol.</li>
<li>Take without regard to meals.</li></ul></td></tr></tbody></table>